Regenxbio Inc (RGNX)
8.76
-0.03
(-0.34%)
USD |
NASDAQ |
Nov 04, 16:00
8.765
0.00 (0.00%)
Pre-Market: 20:00
Regenxbio Cash from Financing (Quarterly): -9.445M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -9.445M |
| March 31, 2024 | 120.72M |
| December 31, 2023 | -11.96M |
| September 30, 2023 | -4.805M |
| June 30, 2023 | -9.162M |
| March 31, 2023 | -9.037M |
| December 31, 2022 | -8.92M |
| September 30, 2022 | -5.417M |
| June 30, 2022 | -7.669M |
| March 31, 2022 | -6.834M |
| December 31, 2021 | -7.616M |
| September 30, 2021 | -2.283M |
| June 30, 2021 | -6.137M |
| March 31, 2021 | 211.29M |
| December 31, 2020 | 194.17M |
| September 30, 2020 | 1.46M |
| June 30, 2020 | 1.825M |
| March 31, 2020 | 2.761M |
| December 31, 2019 | 1.549M |
| Date | Value |
|---|---|
| September 30, 2019 | 1.333M |
| June 30, 2019 | 1.367M |
| March 31, 2019 | 4.127M |
| December 31, 2018 | 5.288M |
| September 30, 2018 | 191.81M |
| June 30, 2018 | 3.175M |
| March 31, 2018 | 4.166M |
| December 31, 2017 | 1.741M |
| September 30, 2017 | 0.606M |
| June 30, 2017 | 10.73M |
| March 31, 2017 | 71.52M |
| December 31, 2016 | -0.055M |
| September 30, 2016 | 0.044M |
| June 30, 2016 | 0.109M |
| March 31, 2016 | 0.021M |
| December 31, 2015 | -2.424M |
| September 30, 2015 | 147.65M |
| June 30, 2015 | 68.06M |
| March 31, 2015 | 26.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.96M
Minimum
Dec 2023
211.29M
Maximum
Mar 2021
23.39M
Average
-5.417M
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 39.92M |
| Catalyst Pharmaceuticals Inc | 1.157M |
| Vertex Pharmaceuticals Inc | -358.60M |
| Edgewise Therapeutics Inc | 1.952M |
| Entrada Therapeutics Inc | 101.37M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -45.50M |
| Cash from Investing (Quarterly) | -0.268M |
| Free Cash Flow | -194.72M |
| Free Cash Flow Per Share (Quarterly) | -0.9085 |
| Free Cash Flow to Equity (Quarterly) | -45.97M |
| Free Cash Flow Yield | -48.25% |